WALTHAM, Mass., Nov. 1, 2018 /PRNewswire/ -- Syndax
Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:
SNDX), a clinical stage biopharmaceutical company developing an
innovative pipeline of cancer therapies, today announced that the
Company's Menin-MLLr program will be featured during two
presentations at the 60th American Society of Hematology
(ASH) Annual Meeting being held December
1-4, 2018 in San Diego,
California.
Oral Presentation Details:
Title: MLL-Menin Inhibition Reverses Pre-Leukemic
Progenitor Self-Renewal Induced By NPM1 Mutations and Prevents AML
Development
Presenter: Hannah Uckelmann, Ph.D., Dana-Farber Cancer
Institute
Session Name: 602. Disordered Gene Expression in Hematologic
Malignancy, including Disordered Epigenetic Regulation: Single Cell
Profiling/Actionable Leukemia Targets
Session Date: Monday, December
3, 2018
Session Time: 7:00 a.m. - 8:30 a.m. PT
Presentation Time: 8:15 a.m. PT
Publication Number: 546
Location: San Diego
Convention Center, Room 9
Scientific Spotlight Session Details:
Title: Targeting Chromatin Complexes in MLL Rearranged
Leukemia
Presenter: Scott Armstrong,
M.D., Ph.D., Dana-Farber Cancer Institute
Session Name: Biochemical and Genetic Insights Into
MLL/11q23 Translocation Leukemia
Session Date: Sunday, December 2,
2018
Session Time: 4:30 p.m. - 6:00 p.m. PT
Location: San Diego
Convention Center, Room 9
About MLL Rearranged Leukemias
Rearrangements of the MLL gene give rise to an acute leukemia,
MLL-r. MLL-r occurs in ~80% of infant acute leukemias and up to 10%
of adult acute leukemias. It is associated with a poor prognosis,
with less than 40% of infants with MLL-r surviving past 5 years.
MLL rearrangements produce fusion proteins that require interaction
with a protein called Menin in order to drive leukemic cancer
growth. Disruption of the Menin-MLL-r interaction has been shown to
halt the growth of MLL-r leukemic cells. MLL-r leukemias are
routinely diagnosed through currently available cytogenetic
screening techniques in leukemic cells, but there are currently no
approved therapies indicated for MLL-r leukemias.
About NPM1c Acute Myeloid Leukemia
NPM1c represents another discrete form of acute myeloid leukemia
(AML) distinguished by point mutations in the NPM1 gene that drives
the leukemic phenotype. NPM1c is the most common type of
cytogenetically normal AML and represents ~30% of all diagnosed
AML. This subtype of AML has a poor prognosis, with a 5-year
overall survival rate of ~50%. Similar to MLL-r leukemias, NPM1c
AML is highly dependent on the expression of specific developmental
genes, shown to be negatively impacted by inhibitors of the
menin-MLL1 interaction. NPM1c AML is routinely diagnosed through
currently available screening techniques in leukemic cells, but
there are currently no approved therapies indicated for NPM1c
AML.
About Syndax Pharmaceuticals, Inc.
Syndax Pharmaceuticals is a clinical stage biopharmaceutical
company developing an innovative pipeline of cancer therapies. The
Company is developing its lead product candidate, entinostat, a
once-weekly, oral, small molecule, class I HDAC inhibitor, in
combination with exemestane and several approved PD-1/PD-(L)1
antagonists. The Company's pipeline also includes SNDX-6352, a
monoclonal antibody that blocks the colony stimulating factor 1
(CSF-1) receptor, as well as a portfolio of potent and selective
inhibitors targeting the binding interaction of Menin with MLLr.
For more information, please visit www.syndax.com or follow the
Company on Twitter and LinkedIn.
Syndax's Cautionary Note on Forward-Looking
Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Words such as "may," "will," "expect," "plan," "anticipate,"
"estimate," "intend," "believe" and similar expressions (as well as
other words or expressions referencing future events, conditions or
circumstances) are intended to identify forward-looking statements.
These forward-looking statements are based on Syndax's expectations
and assumptions as of the date of this press release. Each of these
forward-looking statements involves risks and uncertainties. Actual
results may differ materially from these forward-looking
statements. Forward-looking statements contained in this press
release include, but are not limited to, statements about the
progress, timing, clinical development and scope of clinical trials
and the reporting of clinical data for Syndax's product candidates,
and the potential use of our product candidates to treat various
cancer indications. Many factors may cause differences between
current expectations and actual results including unexpected safety
or efficacy data observed during preclinical or clinical studies,
clinical trial site activation or enrollment rates that are lower
than expected, changes in expected or existing competition, changes
in the regulatory environment, failure of Syndax's collaborators to
support or advance collaborations or product candidates and
unexpected litigation or other disputes. Other factors that may
cause Syndax's actual results to differ from those expressed or
implied in the forward-looking statements in this press release are
discussed in Syndax's filings with the U.S. Securities and Exchange
Commission, including the "Risk Factors" sections contained
therein. Except as required by law, Syndax assumes no obligation to
update any forward-looking statements contained herein to reflect
any change in expectations, even as new information becomes
available.
Syndax Contacts
Investor Contact
Melissa Forst
Argot Partners
melissa@argotpartners.com
Tel 212.600.1902
Media Contact
David Rosen
Argot Partners
david.rosen@argotpartners.com
Tel 212.600.1902
SNDX-G
View original
content:http://www.prnewswire.com/news-releases/syndax-pharmaceuticals-announces-presentations-at-the-60th-american-society-of-hematology-annual-meeting-300742676.html
SOURCE Syndax Pharmaceuticals, Inc.